Selank is a cognitive & neuro research compound currently in stock directly from a verified Chinese manufacturer. Every batch is HPLC-verified and shipped with a Certificate of Analysis (COA). Sourcing is direct — no intermediaries. Minimum order value is $600 USD. International shipping available.
Selank is a synthetic heptapeptide anxiolytic-nootropic compound developed at the Institute of Molecular Genetics (IMG), Russian Academy of Sciences, by a research programme led by Nikolai Myasoedov and colleagues. Its sequence — Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ — is derived from the immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a stabilising Pro-Gly-Pro tripeptide extension at the C-terminus. Tuftsin is a natural spleen-produced tetrapeptide with demonstrated immunomodulatory activity; the extension in Selank was designed to increase proteolytic stability and extend biological half-life while retaining tuftsin-like activity. Selank is registered as a pharmaceutical in Russia for anxiety disorders and mild cognitive impairment, providing clinical context that is rare for compounds in this class.
Selank's pharmacological profile spans two primary research areas: anxiolytic activity via GABAergic and serotonergic modulation, and nootropic/neuroprotective activity via BDNF upregulation and enkephalin metabolism. Electrophysiological studies in rat hippocampal slice preparations document increased GABAergic inhibitory postsynaptic currents following Selank administration, consistent with the anxiolytic behavioural phenotype observed in elevated plus maze (EPM), light-dark box, and open-field animal models. Selank does not bind GABA-A receptor benzodiazepine sites in direct radioligand binding assays, suggesting an indirect mechanism involving GABA system modulation rather than direct agonism.
PeptidesFromChina.co supplies research-grade Selank as lyophilized powder at ≥98% purity verified by HPLC and confirmed by mass spectrometry. Certificates of Analysis per batch. Wholesale quantities available on request. For laboratory research use only.
| Chemical Class | Synthetic Anxiolytic Heptapeptide / Tuftsin Analogue |
|---|---|
| CAS Number | 129954-34-3 |
| Molecular Formula | C₃₃H₅₇N₁₁O₉ |
| Molecular Weight | 751.86 Da |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro-NH₂ (7 amino acids) |
| Parent Compound | Tuftsin (Thr-Lys-Pro-Arg) + Pro-Gly-Pro stabilising extension |
| Developed by | Institute of Molecular Genetics, Russian Academy of Sciences |
| Synonyms | TP-7 (development code) |
| Storage | -20°C lyophilized; 4°C reconstituted (up to 14 days) |
| Name | Strength | Pack Size | Purity | Availability | Price (USD) |
|---|---|---|---|---|---|
| Selank | 5 mg | 10 vials | ≥98% | In Stock | $62.00 |
| Selank | 10 mg | 10 vials | ≥98% | In Stock | $82.00 |
Testing method: HPLC / LC-MS. Every batch is tested before shipment. Purity ≥99% confirmed per batch.
Certificate of Analysis (COA) is included with every order. Documentation covers purity, molecular weight, and batch identification.
Selank's anxiolytic activity has been characterised in standard rodent behavioural models including the elevated plus maze (EPM), forced swim test (FST), open field test (OFT), and light-dark emergence box. In EPM assays, Selank at 300 μg/kg in rats produces open arm time increases comparable to diazepam at sub-maximal doses, without sedation or motor impairment endpoints. Electrophysiological studies in hippocampal slices report enhanced IPSP amplitude and frequency following bath application, attributed to indirect GABAergic potentiation. Benzodiazepine receptor binding assays (³H-flunitrazepam displacement) confirm that Selank does not displace benzodiazepines — indicating its mechanism is distinct from classical anxiolytics.
Selank upregulates brain-derived neurotrophic factor (BDNF) mRNA and protein in hippocampal and prefrontal cortex tissue in rodent models, as measured by RT-PCR and ELISA. BDNF is a key mediator of synaptic plasticity, neuronal survival, and long-term potentiation (LTP) — processes central to learning and memory consolidation. BDNF upregulation by Selank is studied as a mechanism for its reported nootropic effects (improved maze learning, memory retention in water maze tests) in normal and aged rodent models. The TrkB receptor pathway — the primary BDNF signal transducer — is examined using TrkB antagonists (ANA-12) to confirm whether BDNF induction mediates the behavioural effects.
Selank inhibits the enzymatic degradation of enkephalins — endogenous opioid pentapeptides — by suppressing the activity of enkephalin-degrading aminopeptidase N (APN/CD13) and neutral endopeptidase (NEP/CD10). In cell-free enzyme assays and cell culture models, Selank prolongs the half-life of exogenously applied Leu-enkephalin and Met-enkephalin, documented by HPLC-based degradation assays. The functional consequence — increased extracellular enkephalin signalling at μ and δ opioid receptors in limbic regions — is a proposed mechanism for both the anxiolytic and mood-stabilising effects observed in behavioural models.
As a tuftsin analogue, Selank retains some of the parent tetrapeptide's immunomodulatory activity. Tuftsin is a natural activator of phagocytosis, NK cell activity, and macrophage cytokine production. Studies comparing Selank and native tuftsin in macrophage models (peritoneal macrophages, RAW264.7) show Selank produces tuftsin-like enhancement of phagocytic index and IL-2 production, with improved duration of effect attributable to its greater proteolytic resistance. This immunomodulatory strand of research is studied independently of the neurological effects and is relevant to the compound's potential in infectious disease and oncology immune research.
Benzodiazepines are direct positive allosteric modulators of GABA-A receptors at the benzodiazepine binding site, producing sedation, muscle relaxation, and anxiolysis as part of the same pharmacological action. Selank does not bind the GABA-A benzodiazepine site in radioligand displacement assays, and does not produce sedation or motor impairment at anxiolytic doses in rodent models. Its mechanism appears to involve indirect GABA system modulation, BDNF upregulation, and enkephalin stabilisation — a multi-target profile distinct from classical GABA-A direct agonism.
Selank and Semax were both developed at the Institute of Molecular Genetics, Russian Academy of Sciences, in the same peptide bioregulator research programme. Both are registered pharmaceuticals in Russia (nasal formulations). Selank is derived from tuftsin and has a primarily anxiolytic-immunomodulatory profile. Semax is derived from ACTH(4-7) and has a primarily nootropic-neuroprotective profile via BDNF and nerve growth factor (NGF) upregulation. They are studied as complementary rather than redundant compounds — Selank for anxiety/stress-related endpoints, Semax for cognitive enhancement and neuroprotection.
Published rodent studies report active doses of Selank typically in the range 100–300 μg/kg by intraperitoneal or intranasal administration. EPM and FST protocols use doses of 150–300 μg/kg in Wistar rats as the standard effective range. These doses are derived from the published IMG studies (Semenova et al., Medvedev et al.) and should be confirmed against current literature for the specific rodent strain and administration route used in a given study design.
Yes. Selank is available through PeptidesFromChina.co on a B2B wholesale basis. Purity ≥98% by HPLC, confirmed by ESI-MS. Certificates of Analysis per batch. Pricing and minimum order quantities provided on request after account verification.
For laboratory research use only. Not for human or veterinary use. PeptidesFromChina.co is a B2B wholesale supplier operating under strict research-use-only terms. All products are sold exclusively for in vitro and preclinical research purposes.